Since the enactment of the Biologics Price Competition and Innovation Act (BPCIA), the Federal Drug Administration (FDA) has approved more than 20 biosimilar products, and, as the market has grown, litigation activity concerning biosimilars has increased rapidly. Signed into law as part of the Affordable Care Act on March 23, 2010, the BPCIA is codified …